FOSAPREPITANT FOR INJECTION DIN 02549379
Status: Marketed
Holder: JUNO PHARMACEUTICALS CORP.
Health Canada record
| Active ingredient(s) | FOSAPREPITANT (FOSAPREPITANT DIMEGLUMINE) 150 MG |
|---|---|
| Dosage form | Powder For Solution |
| Route | Intravenous |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | A04AD OTHER ANTIEMETICS |
| Original market date | 07-Aug-2025 |
| Current status date | 07-Aug-2025 |
| Source | Health Canada DPD |
Establishment licence of the holder
Juno Pharmaceuticals Corp. (now Juno Pharma Canada Inc.) — licence 3-002647, not currently licensed, last inspection rating C (2025-01-21).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing FOSAPREPITANT (FOSAPREPITANT DIMEGLUMINE)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02363356 | EMEND IV | MERCK CANADA INC | Powder For Solution | FOSAPREPITANT (FOSAPREPITANT DIMEGLUMINE) 150 MG | Marketed |
| 02436264 | FOSAPREPITANT | APOTEX INC | Powder For Solution | FOSAPREPITANT (FOSAPREPITANT DIMEGLUMINE) 150 MG | Approved |
| 02324679 | EMEND IV | MERCK CANADA INC | Powder For Solution | FOSAPREPITANT (FOSAPREPITANT DIMEGLUMINE) 115 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 33632 | 2024-07-11 | Abbreviated New Drug Submission (ANDS) |